Genta Incorporated Release: Independent Analysis Of EORTC Trial Confirms Survival Impact Of Biomarker Identified In Phase 3 Trial Of Genasense(R) In Melanoma
19 Sep 2006
BERKELEY HEIGHTS, N.J., Sept. 19 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA - News) announced the presentation of a collaborative study by Genta and the Melanoma Group of the European Organization for the Research and Treatment of Cancer (EORTC). The results confirmed the strong relationship between patient survival and a biomarker that was prospectively studied in the randomized Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. The results were presented at a scientific meeting, Perspectives in Melanoma X and the Third International Melanoma Research Congress, which was held in The Netherlands.
Organizations
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.